SoftMaxx AI sells no peptides and takes no vendor money.
No supporting study We found no study of a peptide sold for looks that measured facial attractiveness, facial proportions or the jaw in adults. Growth-hormone therapy in children with growth disorders has been studied for facial ratios and jaw growth (reported as preliminary trends); several topical peptide trials measured facial wrinkles. So most looksmaxxing claims borrow from some other outcome.[1][2][3][4]
The tier describes evidence that a peptide sold for looks changes adult face shape or attractiveness (we found none); stronger evidence here includes, among others, weight [5], wrinkle [2] [3], collagen [6] [7] [8] and MK-677 trials [9] [10], acromegaly [11] and drug labels [12] [13].
The verdict
SoftMaxx AI reviewed 74 entries (peptides, blends and peptide-adjacent compounds) and every paper we could verify on PubMed. We found no study of a peptide sold for looks that measured facial attractiveness, facial proportions or the jaw as an outcome. Growth-hormone therapy in children, a protein hormone rather than a looks peptide, has measured facial ratios and jaw growth, reported as preliminary trends [1]. The closest for looks peptides are topical trials that measured facial wrinkles [2][3].
So this page ranks peptides by how much human evidence exists, not by how good they are said to look. A high tier means more human evidence exists for some outcome. It never means a better face.
- Common belief
Semaglutide gives you a sharper face
No supporting study We found no semaglutide trial that measured the face. The two pieces on "Ozempic face" cited here are commentary on facial volume loss after rapid weight loss.[15][16] - Common belief
MK-677 grows your jaw
No supporting study We found no MK-677 trial that measured facial bones. A 2-year trial in adults aged 60 to 81 recorded transient, mild leg swelling (edema).[9]
The tiers, by evidence
| Peptide | What people want from it | Best human evidence | Tier |
|---|---|---|---|
| Semaglutide, tirzepatide | Leaner face | Large trials for weight; none we found for the face | 1. Approved, for other conditions [5] [12] [13] |
| Oral collagen peptides | Skin | Many small trials; effect absent in trials without drug-company funding | 2. Human trials, contested [6] [8] |
| Matrixyl (pal-KTTKS), palmitoyl pentapeptide-4, argireline | Fewer fine lines | A few small, short trials | 2. Human trials, small [2] [4] [3] |
| GHK-Cu (on the skin) | Firmer skin | Few, small clinical studies | 3. Tiny human data [17] [18] |
| BPC-157 | Skin, recovery | Five small clinical studies per FDA, two placebo-controlled; none on skin | 3. Tiny human data [19] |
| Melanotan II | Tan | A 1996 pilot in 3 men, then case reports | 3. Tiny human data, documented harms [20] [21] [22] |
| TB-500, KPV | Recovery, calmer skin | FDA found no human exposure data | 4. Animal or cell only [23] [24] [25] [26] [27] |
| GLOW, KLOW, "Wolverine" blends | Glow, recovery | We found no human study of GLOW or KLOW. For BPC-157 with TB-500, the Wolverine pair as sellers describe it, we found one rat study, a retrospective chart review in which 4 knee-pain patients got BPC-157 with thymosin-beta-4 (TB4), and one FDA adverse-event report on a BPC-157 and TB-500 product; we found no controlled human study of the pair | 5. None found (GLOW, KLOW); 3. Tiny human data (the Wolverine pair) [25] [28] [19] |
The sections below give the sources for each row.
- Human RCT In the STEP 1 trial, semaglutide produced about 15% weight loss versus 2.4% on placebo at 68 weeks.[5]
- Expert review A 2025 meta-analysis of 23 collagen trials found no skin benefit in trials without pharmaceutical-company funding or in high-quality trials.[8]
- Human, small or uncontrolled FDA's July 2026 briefing lists five clinical studies of BPC-157, two of them placebo-controlled, all small and short. A 2025 systematic review counted 35 preclinical studies and 1 clinical study.[19][29][28][30][31]
- Regulator document FDA's July 2026 briefing found no clinical studies or human exposure data for TB-500, including no human pharmacokinetic data.[23]
- Regulator document FDA states it has not identified any human exposure data for KPV.[24]
Injected "glow" and recovery peptides: almost no human data
Health Canada lists BPC-157, TB-500, KPV and GHK-Cu among unauthorized injectable peptides it has seized, and says such products are often promoted online, including for injury recovery and athletic performance [32].
Their human record runs from five small clinical studies (BPC-157) to no human exposure data at all (TB-500, KPV), per FDA [19] [23] [24]. FDA's briefing lists no human study of BPC-157 on skin [19]. One of the three reports for BPC-157 in FDA's drug adverse-event database (FAERS), on a product that also contained TB-500, was a skin reaction [19]; FDA's TB-500 briefing notes two more reports on blended TB-500 and BPC-157 in its food and supplement system, with no safety assessment [23]. The full breakdown is on the GLOW and KLOW pages.
- Claim as marketed
GLOW and KLOW are tested skin injections
No supporting study We found no published study of the GLOW or KLOW blends in people, animals or cells. For one of their ingredients, TB-500, FDA found no human exposure data.[23] - Case report One of the three reports for BPC-157 in FDA's drug adverse-event database (FAERS) describes diffuse skin and gum darkening after a product that also contained TB-500. It came back when the person used it again.[19]
- Animal In a controlled rat study of BPC-157 with TB-500 (32 rats, 8 per group), the pair gave no added benefit over either alone.[25]
Melanotan II: the tanning peptide with documented harms
Melanotan II is unlicensed [33], and we found no FDA-approved product containing it in Drugs@FDA [34]. The earliest human study we found was a 1996 pilot in 3 men [20].
Since then, the reports we found are mostly case reports of harm [21] [22] [35] [33]. Vials sold illegally online held less drug than labelled, and vials from two of three shops held unknown impurities [36].
- Human, small or uncontrolled The phase I pilot of Melanotan II enrolled 3 healthy men; 2 of 3 showed more skin pigment.[20]
- Case report One case report describes new moles and darkening of existing moles 24 hours after a single injection of Melanotan II. Another report, for which PubMed lists no abstract, is titled as eruptive moles after melanotan injection, without naming which melanotan.[21][22]
- Case report A melanoma has been reported in a Melanotan II user; the woman also used sunbeds, so cause is not established. Another report, for which PubMed lists no abstract, is titled melanotan-associated melanoma, without naming which melanotan.[35][33]
- Common belief
A Melanotan tan protects your skin
Expert review A 2025 review states that activating the melanin receptor may lower melanoma risk but does not stop melanoma, especially in people with risk factors.[37]
MK-677, growth hormone and follistatin: the jaw myths
We found no trial showing that growth-hormone drugs give adults a bigger jaw.
In adults, jaw and facial bone growth from excess growth hormone is documented in acromegaly, a chronic disease whose signs progress slowly [11]. Claims about hard mewing deserve the same caution. In a lab analysis of 17 black-market "follistatin 344" products, only 9 contained follistatin [38]. The jawline page covers this in full.
- Human RCT In a 2-year trial in older adults, MK-677 raised lean mass by about 1.1 kg. It did not reduce body fat, and it raised fasting glucose.[9]
- Human RCT A hip-fracture trial of MK-677 was stopped early for a heart-failure signal.[10]
- Expert review Jaw (mandibular) overgrowth is reported in 22–24% of people with acromegaly, a disease of excess growth hormone. Thickened frontal bones and a protruding brow are among its common facial changes.[11]
GLP-1 drugs and "Ozempic face"
Semaglutide and tirzepatide are FDA-approved drugs [39]: semaglutide as Ozempic for diabetes [15] and as Wegovy to reduce excess body weight [12]. Your prescriber sets your dose; the Wegovy label is on DailyMed [12].
Rapid weight loss on semaglutide can deplete facial volume and fat [15]. We found no trial that tested the face directly. Hair loss is listed as a side effect on the Wegovy label [12].
- Common belief
"Ozempic face" is a special effect of the drug
Expert review Commentaries tie "Ozempic face" to rapid weight loss on the drug that depletes facial volume and fat. One asks whether it is a new drug effect or a natural result of rapid weight loss, and leaves that open.[15][16] - Drug label In the label's pooled adult weight-loss trials, hair loss was reported in 3.3% of people on Wegovy 2.4 mg versus 1% on placebo.[12]
Oral collagen: pooled gains, funding questions
Oral collagen is used as a supplement [6]. Meta-analyses have pooled 19 to 26 randomized skin trials of it [6][7].
The catch is who paid for them. In a 2025 meta-analysis, the benefit was absent in trials without pharmaceutical-company funding and in high-quality trials [8].
- Expert review Meta-analyses pooling many small trials report better skin hydration and elasticity with oral collagen.[6][7]
- Human RCT In one trial of 114 women, a specific bioactive collagen peptide product reduced eye-wrinkle volume by about 20% over 8 weeks.[40]
- Expert review A 2025 meta-analysis found no skin benefit in trials without pharmaceutical-company funding or in high-quality trials.[8]
Topical peptides: small, short trials
Trials of peptide creams and serums measured fine lines and wrinkles over weeks, not face shape [2][3]. The skin guide ranks them one by one.
- Human RCT A 12-week split-face trial of palmitoyl pentapeptide (pal-KTTKS) in 93 women reported fewer fine lines than the same moisturizer without peptide.[2]
- Human RCT Argireline results are mixed: positive in a 60-person trial and not significant in a 19-person split-face study. A three-arm trial of 21 people in all found a palmitoyl pentapeptide-4 cream did better than an acetylhexapeptide-3 cream; its abstract does not state whether that is the same substance as argireline.[3][4][41]
- Expert review Two reviews describe the human evidence for topical GHK-Cu as thin, with few clinical studies.[17][18]
Further reading
For the broader idea, see what softmaxxing is and looksmaxxing vs softmaxxing.
Doses used in studies (not a recommendation)
Each row comes from the cited source: a study dose, a safety-review limit or a registered trial's planned dose, as labelled. Where the abstract states no amount, the row says so. They are a record of what was reported, not dosing instructions, and nothing here says what you should take.
| Studied in | Route | Amount reported | How often | How long | n | Source |
|---|---|---|---|---|---|---|
| human | oral | 2.5 g collagen peptides Study dose | once daily | 8 weeks | 114 | [40] Women aged 45–65; eye-wrinkle trial. |
| human | topical (split-face moisturizer) | 3 ppm pal-KTTKS (palmitoyl pentapeptide) Study dose | not stated in the abstract | 12 weeks | 93 | [2] Women aged 35–55 with photoaged facial skin. |
Side effects and risks
- Case report Melanotan II: new and darkening moles in a case report; a melanoma in a user who also used sunbeds; two more reports, without PubMed abstracts, are titled for melanotan without naming which[21][22][35][33]
- Case report Product with BPC-157 and TB-500: diffuse skin and gum darkening (one of three reports for BPC-157 in FDA's drug adverse-event database, FAERS)[19]
- Human RCT MK-677: higher fasting glucose, lower insulin sensitivity, fluid retention[9]
- Human RCT MK-677: heart-failure signal that stopped a hip-fracture trial early[10]
- Drug label Semaglutide (Wegovy 2.4 mg): hair loss, 3.3% vs 1% on placebo in pooled adult trials[12]
- Regulator document Several injected unapproved peptides: FDA flags possible immune reactions linked to impurities or aggregation[24]
Regulatory status (checked 2026-10-01 to 2026-10-03)
- United States (FDA)Semaglutide is FDA-approved as Ozempic and Wegovy (prescription drugs). (DailyMed:
OZEMPIC (semaglutide) injection — Prescribing Information
, captured 2026-10-03; DailyMed:WEGOVY (semaglutide) injection; WEGOVY (semaglutide) tablets — Prescribing Information
, captured 2026-10-03) Tirzepatide is FDA-approved as Mounjaro and Zepbound (prescription drugs). (DailyMed:MOUNJARO (tirzepatide) injection — Prescribing Information
, captured 2026-10-03; DailyMed:ZEPBOUND (tirzepatide) injection — Prescribing Information
, captured 2026-10-03) We found no FDA-approved product containing ibutamoren (MK-677) in Drugs@FDA (searched 2026-10-01). (FDA:Drugs@FDA search: ibutamoren — no approved product found
, captured 2026-10-01) FDA lists Ibutamoren mesylate (MK-677) in 503A Category 2, “Bulk Drug Substances that Raise Significant Safety Risks”, added 2023-09-29. (FDA:Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act
, captured 2026-10-03; FDA:Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
, captured 2026-10-03) We found no FDA-approved product containing BPC-157 in Drugs@FDA (searched 2026-10-01). (FDA:Drugs@FDA search: bpc-157 — no approved product found
, captured 2026-10-01) FDA removed BPC-157 from 503A Category 2 on 2026-04-22 after the nominations were withdrawn; FDA’s safety page still lists it under “Bulk drug substances nominated but withdrawn”. (FDA:Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act
, captured 2026-10-03; FDA:Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
, captured 2026-10-03) We found no FDA-approved product containing TB-500 in Drugs@FDA (searched 2026-10-01). (FDA:Drugs@FDA search: tb-500 — no approved product found
, captured 2026-10-01) FDA removed Thymosin beta-4 fragment (LKKTETQ), 'TB-500' from 503A Category 2 on 2026-04-22 after the nominations were withdrawn; FDA’s safety page still lists it under “Bulk drug substances nominated but withdrawn”. (FDA:Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act
, captured 2026-10-03; FDA:Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
, captured 2026-10-03) We found no FDA-approved product containing KPV in Drugs@FDA (searched 2026-10-01). (FDA:Drugs@FDA search: kpv — no approved product found
, captured 2026-10-01) FDA removed KPV from 503A Category 2 on 2026-04-22 after the nominations were withdrawn; FDA’s safety page still lists it under “Bulk drug substances nominated but withdrawn”. (FDA:Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act
, captured 2026-10-03; FDA:Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
, captured 2026-10-03) We found no FDA-approved product containing Melanotan II in Drugs@FDA (searched 2026-10-01). (FDA:Drugs@FDA search: melanotan-ii — no approved product found
, captured 2026-10-01) FDA removed Melanotan II from 503A Category 2 on 2026-04-22 after the nominations were withdrawn; FDA’s safety page still lists it under “Bulk drug substances nominated but withdrawn”. (FDA:Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act
, captured 2026-10-03; FDA:Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
, captured 2026-10-03) We found no FDA-approved product containing GHK-Cu in Drugs@FDA (searched 2026-10-01). (FDA:Drugs@FDA search: ghk-cu — no approved product found
, captured 2026-10-01) FDA lists GHK-Cu (except for injectable routes of administration) in 503A Category 1, “Bulk Drug Substances Under Evaluation” (list updated 2026-05-14). (FDA:Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act
, captured 2026-10-03) In the US, dietary supplement firms are responsible for evaluating the safety and labeling of their products before marketing, and FDA can act against a product that is adulterated or misbranded after it reaches the market. (FDA:Dietary Supplements
, captured 2026-10-03) - CanadaOzempic and Wegovy (semaglutide) have Drug Identification Numbers in Health Canada’s Drug Product Database. (Health Canada:
Health Canada Drug Product Database: OZEMPIC (semaglutide) — Drug Identification Numbers listed
, captured 2026-10-01; Health Canada:Health Canada Drug Product Database: WEGOVY (semaglutide) — Drug Identification Numbers listed
, captured 2026-10-01) Mounjaro and Zepbound (tirzepatide) have Drug Identification Numbers in Health Canada’s Drug Product Database. (Health Canada:Health Canada Drug Product Database: MOUNJARO (tirzepatide) — Drug Identification Numbers listed
, captured 2026-10-01; Health Canada document, captured 2026-10-01) We found no product containing ibutamoren (MK-677) in Health Canada’s Drug Product Database (searched 2026-10-01). (Health Canada:Health Canada Drug Product Database search: ibutamoren — no product found
, captured 2026-10-01) We found no product containing BPC-157 in Health Canada’s Drug Product Database (searched 2026-10-01). (Health Canada:Health Canada Drug Product Database search: bpc-157 — no product found
, captured 2026-10-01) We found no product containing TB-500 in Health Canada’s Drug Product Database (searched 2026-10-01). (Health Canada:Health Canada Drug Product Database search: tb-500 — no product found
, captured 2026-10-01) We found no product containing KPV in Health Canada’s Drug Product Database (searched 2026-10-01). (Health Canada:Health Canada Drug Product Database search: kpv — no product found
, captured 2026-10-01) We found no product containing Melanotan II in Health Canada’s Drug Product Database (searched 2026-10-01). (Health Canada:Health Canada Drug Product Database search: melanotan-ii — no product found
, captured 2026-10-01) We found no product containing GHK-Cu in Health Canada’s Drug Product Database (searched 2026-10-01). (Health Canada:Health Canada Drug Product Database search: ghk-cu — no product found
, captured 2026-10-01) Health Canada named GHK-Cu in “Think twice before injecting peptides bought online: unauthorized products can seriously harm you”. (Health Canada:Think twice before injecting peptides bought online: unauthorized products can seriously harm you
, captured 2026-10-03) Health Canada named GHK-Cu in an advisory on unauthorized injectable peptide drugs seized from a seller (page last updated 2025-08-01). (Health Canada advisory: unauthorized injectable peptide drugs seized (2025), captured 2026-10-03) Health Canada named GHK-Cu in an advisory on unauthorized injectable peptide drugs seized from a business in Calgary, Alberta (page last updated 2025-04-02). (Health Canada advisory: unauthorized injectable peptide drugs seized in Calgary (2025), captured 2026-10-03) Health Canada named GHK-Cu in “GHK-Cu & BPC-157 powder: Unauthorized active pharmaceutical ingredients”. (Health Canada document, captured 2026-10-03) - Sport (WADA)Semaglutide is not on the 2026 WADA Prohibited List. (WADA:
World Anti-Doping Code International Standard Prohibited List 2026
, captured 2026-10-03) Tirzepatide is not on the 2026 WADA Prohibited List. (WADA:World Anti-Doping Code International Standard Prohibited List 2026
, captured 2026-10-03) Ibutamoren is named on the 2026 WADA Prohibited List (S2.2.4). (WADA:World Anti-Doping Code International Standard Prohibited List 2026
, captured 2026-10-03) BPC-157 is named on the 2026 WADA Prohibited List (S0). (WADA:World Anti-Doping Code International Standard Prohibited List 2026
, captured 2026-10-03) TB-500 is named on the 2026 WADA Prohibited List (S2.3). (WADA:World Anti-Doping Code International Standard Prohibited List 2026
, captured 2026-10-03) KPV is not named on the 2026 WADA Prohibited List; by our reading it falls under S0, non-approved substances. (WADA:World Anti-Doping Code International Standard Prohibited List 2026
, captured 2026-10-03) Melanotan II is not named on the 2026 WADA Prohibited List; by our reading it falls under S0, non-approved substances. (WADA:World Anti-Doping Code International Standard Prohibited List 2026
, captured 2026-10-03) WADA’s Prohibited List does not name GHK-Cu. WADA states that topical cosmetic products may contain prohibited peptides or growth factors and that using cosmetic products containing such substances is prohibited; we found no WADA statement on whether GHK-Cu is one of them. (WADA:World Anti-Doping Code International Standard Prohibited List 2026
, captured 2026-10-03; WADA:The Prohibited List
, captured 2026-10-03) Collagen peptides are not on the 2026 WADA Prohibited List. (WADA:World Anti-Doping Code International Standard Prohibited List 2026
, captured 2026-10-03)
Official sources: FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
· FDA: Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act
· WADA: World Anti-Doping Code International Standard Prohibited List 2026
Report a side effect
If something went wrong after using a health product, tell a clinician. Report side effects to:
- FDA MedWatch (United States)
- Health Canada (report a side effect)
Common questions
What is the best peptide for the face?
We found none shown to change face shape or the jaw, and no study of a peptide sold for looks that measured facial attractiveness, facial proportions or the jaw. The closest data are small topical trials that measured facial wrinkles: 4 weeks for argireline (60 people) and 12 weeks for palmitoyl pentapeptide (93 women).[2][3]
Will semaglutide make my face slimmer or give me a jawline?
We found no trial that measured the face. A facial plastic surgery review says rapid weight loss on semaglutide can lead to "Ozempic face", where facial volume and fat are depleted [15]. Semaglutide is a prescription drug; your prescriber decides if it fits you.[15][16]
Can MK-677 make you taller or grow your jaw?
No trial we found supports it, and none measured facial bones. In a 2-year trial in adults aged 60 to 81 it raised blood sugar, did not reduce body fat and caused mild, transient leg swelling.[9]
Does Melanotan 2 cause cancer or new moles?
New moles and darkening of existing moles are documented in a Melanotan II case report, and a melanoma has been reported in a user who also used sunbeds, so cause is not proven. Two more reports, for which PubMed lists no abstract, are titled for melanotan without naming which. It is unlicensed, and we found no FDA-approved product containing it in Drugs@FDA.[21][22][35][33] Source: FDA: Drugs@FDA search: melanotan-ii — no approved product found
Does collagen powder actually work for skin, or is it just digested?
Some collagen fragments do reach the blood. Pooled trials show gains in hydration and elasticity, but in a 2025 meta-analysis those gains were absent in trials without pharmaceutical-company funding and in high-quality trials.[42][8]
References
References to papers were matched to their PubMed or DOI records. Regulator, label and registry pages were fetched and saved by us; each status line under Regulatory status gives the date its source was captured. "Verified" means the paper exists and is the one named; what it supports is stated next to each claim.
Effects of growth hormone therapy on facial anthropometric features in children with growth disorders: a cohort study.
PubMed 42583639 DOITopical palmitoyl pentapeptide provides improvement in photoaged human facial skin.
PubMed 18492182 DOIThe anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study.
PubMed 23417317 DOIDouble-blind, Randomized Trial on the Effectiveness of Acetylhexapeptide-3 Cream and Palmitoyl Pentapeptide-4 Cream for Crow's Feet.
PubMed 36909866Once-Weekly Semaglutide in Adults with Overweight or Obesity.
PubMed 33567185 DOIEffects of hydrolyzed collagen supplementation on skin aging: a systematic review and meta-analysis.
PubMed 33742704 DOIEffects of Oral Collagen for Skin Anti-Aging: A Systematic Review and Meta-Analysis.
PubMed 37432180 DOIEffects of Collagen Supplements on Skin Aging: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
PubMed 40324552 DOIEffects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.
PubMed 18981485 DOIMK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study.
PubMed 21067829 DOIOral Manifestations and Maxillo-Facial Features in the Acromegalic Patient: A Literature Review.
PubMed 35207363 DOIWEGOVY (semaglutide) injection; WEGOVY (semaglutide) tablets — Prescribing Information
SourceZEPBOUND (tirzepatide) injection — Prescribing Information
SourcePublic Interest in Acetyl Hexapeptide-8: Longitudinal Analysis.
PubMed 38376906 DOIImplications of Ozempic and Other Semaglutide Medications for Facial Plastic Surgeons.
PubMed 37541662 DOINatural Weight Loss or "Ozempic Face": Demystifying A Social Media Phenomenon.
PubMed 38206146 DOITopically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective.
PubMed 39963574 DOIA Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials.
PubMed 42787770 DOIJuly 23-24, 2026, Meeting of the Pharmacy Compounding Advisory Committee – FDA Briefing Document for BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate)
SourceEvaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.
PubMed 8637402 DOIEruptive melanocytic naevi following melanotan injection.
PubMed 19575725 DOIEruptive naevi and darkening of pre-existing naevi 24 h after a single mono-dose injection of melanotan II.
PubMed 24334249 DOIJuly 23-24, 2026, Meeting of the Pharmacy Compounding Advisory Committee – FDA Briefing Document for TB-500-Related Bulk Drug Substances (TB-500 (free base) and TB-500 acetate)
SourceCertain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
SourceEffects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.
PubMed 42542926 DOIPepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.
PubMed 18061177 DOIalpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells.
PubMed 15102092 DOIIntra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.
PubMed 34324435Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.
PubMed 40756949 DOIEffect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.
PubMed 39325560Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.
PubMed 40131143Think twice before injecting peptides bought online: unauthorized products can seriously harm you (Health Canada advisory; lists KPV)
SourceMelanoma associated with the use of melanotan-II.
PubMed 24355990 DOIDrugs@FDA search: melanotan-ii — no approved product found (2026-10-01)
SourceMelanotan-associated melanoma.
PubMed 21564053 DOIIdentification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet.
PubMed 24771717 DOIAn overview of benefits and risks of chronic melanocortin-1 receptor activation.
PubMed 39082868 DOIDetection of black market follistatin 344.
PubMed 31758732 DOIDangers of Injectable Peptides and Other Unregulated "Biohacking" Drugs.
PubMed 42757290Oral intake of specific bioactive collagen peptides reduces skin wrinkles and increases dermal matrix synthesis.
PubMed 24401291 DOIInvestigating the effects of Argireline in a skin serum containing hyaluronic acids on skin surface wrinkles using the Visia® Complexion Analysis camera system for objective skin analysis.
PubMed 38024099 DOIIdentification of food-derived collagen peptides in human blood after oral ingestion of gelatin hydrolysates.
PubMed 16076145 DOI
Keep reading
- Best peptides for skin, ranked by evidence→
- Peptides for jawline: a myth-check→
- GLOW peptide stack: components, evidence and risks→
- KLOW peptide: components, evidence and risks→
- GHK-Cu topical vs injectable: what the evidence shows→
- Peptides for hair growth vs minoxidil and finasteride→
- GHK-Cu before and after: what the trials actually measured→
- New to peptides? Start here→
- All peptide pages, by evidence→